SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Stintzing Sebastian)
 

Sökning: WFRF:(Stintzing Sebastian) > (2024) > A Randomized Phase ...

  • Tabernero, JosepVall dHebron Hosp Campus, Barcelona 08035, Spain.;IOB Quiron, Inst Oncol VHIO, Barcelona, Spain.;UV UCC, Inst Oncol VHIO, IOB Quiron, Barcelona 08035, Spain. (författare)

A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer : The AGENT Trial

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • American Association For Cancer Research (AACR),2024
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-527983
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-527983URI
  • https://doi.org/10.1158/2767-9764.CRC-23-0361DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Purpose:Suboptimal treatment outcomes with 5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate. Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is an immediately active folate and may improve outcomes over the existing standard of care (leucovorin).Experimental Design:AGENT was a randomized, phase III study (NCT03750786). Patients with mCRC were randomized to arfolitixorin (120 mg/m2 given as two intravenous bolus doses of 60 mg/m2) or leucovorin (400 mg/m2 given as a single intravenous infusion) plus 5-FU, oxaliplatin, and bevacizumab. Assessments were performed every 8 weeks. The primary endpoint was the superiority of arfolitixorin for overall response rate (ORR).Results:Between February 2019 and April 2021, 490 patients were randomized (245 to each arm). After a median follow-up of 266 days, the primary endpoint of superiority for ORR was not achieved (48.2% for arfolitixorin vs. 49.4% for leucovorin, Psuperiority = 0.57). Outcomes were not achieved for median progression-free survival (PFS; 12.8 and 11.6 months, P = 0.38), median duration of response (12.2 and 12.9 months, P = 0.40), and median overall survival (23.8 and 28.0 months, P = 0.78). The proportion of patients with an adverse event of grade ≥3 severity was similar between arms (68.7% and 67.2%, respectively), as was quality of life. BRAF mutations and MTHFD2 expression were both associated with a lower PFS with arfolitixorin.Conclusions:The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m2) over leucovorin. However, it provides some useful insights from the first-line treatment setting, including the effect of gene expression on outcomes.Significance:This phase III study compared arfolitixorin, a direct-acting folate, with leucovorin in FOLFOX plus bevacizumab in mCRC. Arfolitixorin (120 mg/m2) did not improve the ORR, potentially indicating a suboptimal dose.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Yoshino, TakayukiNatl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan. (författare)
  • Stintzing, SebastianCharite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany. (författare)
  • de Gramont, AimeryInst Hosp Franco Britannique, Oncol Med, Levallois Perret, France. (författare)
  • Gibbs, PeterSunshine Hosp, Western Hlth, Med Oncol, St Albans, Vic, Australia. (författare)
  • Jonker, Derek J.Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada. (författare)
  • Nygren, PeterUppsala universitet,Cancerprecisionsmedicin(Swepub:uu)peterng (författare)
  • Papadimitriou, ChristosNatl & Kapodistrian Univ Athens, Aretaieion Univ Hosp, Oncol Unit, Athens, Greece. (författare)
  • Prager, Gerald W.Med Univ Wien, Vienna, Austria. (författare)
  • Tell, RogerIsofol Med AB, Gothenburg, Sweden. (författare)
  • Lenz, Heinz-JosefUniv Southern Calif, Keck Sch Med, Div Med Oncol & Colorectal Canc, Los Angeles, CA USA. (författare)
  • Vall dHebron Hosp Campus, Barcelona 08035, Spain.;IOB Quiron, Inst Oncol VHIO, Barcelona, Spain.;UV UCC, Inst Oncol VHIO, IOB Quiron, Barcelona 08035, Spain.Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cancer Research Communications: American Association For Cancer Research (AACR)4:1, s. 28-372767-9764

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy